On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
ACADEMIA
1st Line Statins Likely to Be Recommended for Pediatric Familial Hypercholesterolemia
The Japan Atherosclerosis Society (JAS) and the Japan Pediatric Society are expected to recommend the frontline use of statins for familial hypercholesterolemia (FH) in children in their joint treatment guide being compiled for pediatric FH. The plan was revealed on…
To read the full story
Related Article
ACADEMIA
- Lynparza Got Prostate Cancer OK, but Reimbursement Issues Remain for CDx Costs: Professor
January 22, 2021
- Antitussive Cloperastine Strongly Attacks Cisplatin-Resistant Cancer Cells: Research Group
January 22, 2021
- Japan Reports Mother-to-Infant Cervical Tumor Transmission via Amniotic Fluids
January 7, 2021
- Japan Succeeds in Isolating Novel Coronavirus Variant
January 7, 2021
- NCGM, Fujita Univ. to Join NIH’s Immunoglobulin Trial for COVID-19
December 24, 2020
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…